NRG4

Summary

NRG4 (neuregulin 4, HGNC:29862) is a protein-coding gene on chromosome 15q24.2, encoding Pro-neuregulin-4, membrane-bound isoform (Q8WWG1). Low affinity ligand for the ERBB4 tyrosine kinase receptor.

The neuregulins, including NRG4, activate type-1 growth factor receptors (see EGFR; MIM 131550) to initiating cell-to-cell signaling through tyrosine phosphorylation (Harari et al., 1999 [PubMed 10348342]).

Source: NCBI Gene 145957 — RefSeq curated summary.

At a glance

• GWAS associations: 30
• Clinical variants (ClinVar): 21 total
• MANE Select transcript: NM_138573

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29862
Approved symbol	NRG4
Name	neuregulin 4
Location	15q24.2
Locus type	gene with protein product
Status	Approved
Aliases	HRG4
Ensembl gene	ENSG00000169752
Ensembl biotype	protein_coding
OMIM	610894
Entrez	145957

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 10 nonsense_mediated_decay, 4 protein_coding_CDS_not_defined, 3 protein_coding

ENST00000394907, ENST00000461391, ENST00000472094, ENST00000498750, ENST00000562114, ENST00000563204, ENST00000563582, ENST00000563910, ENST00000565661, ENST00000566417, ENST00000567126, ENST00000567467, ENST00000567936, ENST00000568073, ENST00000568203, ENST00000569343, ENST00000855803

RefSeq mRNA: 1 — MANE Select: NM_138573 NM_138573

CCDS: CCDS10288

Canonical transcript exons

ENST00000394907 — 6 exons

Exon	Start	End
ENSE00001387413	76009200	76009293
ENSE00001519968	76012319	76012424
ENSE00001766554	75940936	75943654
ENSE00002190732	76011221	76011286
ENSE00003538901	75961828	75961974
ENSE00003786523	75955932	75956011

Expression profiles

Bgee: expression breadth ubiquitous, 164 present calls, max score 92.66.

FANTOM5 (CAGE): breadth broad, TPM avg 0.9532 / max 58.3196, expressed in 244 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
151006	0.4860	119
151008	0.2447	83
151007	0.1846	41
151005	0.0379	20

Top tissues by expression

247 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of pancreas	UBERON:0001150	92.66	gold quality
right uterine tube	UBERON:0001302	92.20	gold quality
cerebellar hemisphere	UBERON:0002245	90.17	gold quality
cerebellar cortex	UBERON:0002129	89.92	gold quality
right hemisphere of cerebellum	UBERON:0014890	89.56	gold quality
cerebellum	UBERON:0002037	87.58	gold quality
pancreas	UBERON:0001264	85.13	gold quality
adrenal tissue	UBERON:0018303	83.62	gold quality
secondary oocyte	CL:0000655	83.24	gold quality
left testis	UBERON:0004533	82.78	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	82.62	gold quality
right testis	UBERON:0004534	82.41	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.90	gold quality
hindlimb stylopod muscle	UBERON:0004252	81.78	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	79.72	gold quality
muscle of leg	UBERON:0001383	79.58	gold quality
testis	UBERON:0000473	79.29	gold quality
gastrocnemius	UBERON:0001388	78.66	gold quality
calcaneal tendon	UBERON:0003701	78.41	gold quality
right adrenal gland	UBERON:0001233	76.46	gold quality
Brodmann (1909) area 9	UBERON:0013540	75.89	gold quality
right adrenal gland cortex	UBERON:0035827	75.63	gold quality
right frontal lobe	UBERON:0002810	75.10	gold quality
islet of Langerhans	UBERON:0000006	75.02	gold quality
hypothalamus	UBERON:0001898	74.72	gold quality
body of stomach	UBERON:0001161	74.18	gold quality
anterior cingulate cortex	UBERON:0009835	73.68	gold quality
stomach	UBERON:0000945	73.03	gold quality
left adrenal gland	UBERON:0001234	72.76	gold quality
adenohypophysis	UBERON:0002196	72.70	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	11.58

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

129 targeting NRG4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509

Literature-anchored findings (GeneRIF, showing 27)

• Neuregulin-4 expression is downregulated during urinary bladder cancer progression (PMID:15583696)
• NRG4 overexpression is associated with advanced-stage prostate cancer (PMID:17545517)
• describes a novel splice variant of the NRG4 gene, NRG4A2, which encodes a C-terminal region containing a predicted type I PDZ-binding peptide (PMID:17684490)
• NRG4 was positive in almost all breast cancers studied. (PMID:17962208)
• The recombinant neuregulin 4 induced the tyrosine phosphorylation of HER4. (PMID:21805036)
• Pharmacological inhibition of PI3K/Akt signaling reversed the anti-apoptotic effects of NRG4, confirming the role of this cascade in NRG4-induced cell survival (PMID:23033483)
• NRG4 and its receptor ErbB4 are present in human breast milk and developing human intestine, respectively. Thus, NRG4-ErbB4 signaling may be a novel pathway for therapeutic intervention or prevention in NEC. (PMID:25216938)
• results establish Nrg4 as a brown fat-enriched endocrine factor with therapeutic potential for the treatment of obesity-associated disorders, including type 2 diabetes and nonalcoholic fatty liver disease (NAFLD). (PMID:25401691)
• Nrg4 might have a protective role in the development of Non-alcoholic fatty liver disease (NAFLD). (PMID:26476959)
• High serum Nrg4 levels are associated with type 2 diabetes mellitus. (PMID:27329015)
• circulating Nrg4 concentrations are inversely associated with subclinical atherosclerosis in obese adults; circulating Nrg4 might play a role in identifying patients at high risk for cardiovascular disease (PMID:27819316)
• The circulating Nrg4 level is elevated in the prediabetic and diabetic patients compared to control and is an independent risk factor associated with diabetes. (PMID:27862843)
• Serum NRG4 values were significantly elevated in the Gestational Diabetes Mellitus (GDM) group compared to the control group and is associated with metabolic parameters of GDM. (PMID:29282998)
• Nrg4 is highly and preferentially expressed in healthy adipocytes, while its expression was substantially reduced in obesity. Nrg4 activated endothelial angiogenic functions and angiogenesis both in vitro and in vivo. (PMID:29902456)
• Nrg4 has a role in maintaining systemic metabolic homeostasis at least partially through enhancing adipose tissue angiogenesis (PMID:30195497)
• These findings together suggested that circulating Nrg4 levels were reduced in diabetic peripheral neuropathy patients and Nrg4 may be a novel adipokine associated with inflammation, oxidative stress, and long-term glycemic control in nT2DM patients. (PMID:30322810)
• Study reported for the first time that circulating Nrg4 concentrations were significantly reduced in patients with coronary artery disease (CAD) and Nrg4 levels were lower in the patients with a higher SYNTAX score. These findings indicated that Nrg4 levels were inversely associated with the presence and severity of CAD. (PMID:30393265)
• Median serum NRG4 was significantly lower in patients with end-stage kidney disease. (PMID:31153139)
• Study findings suggested circulating NRG4 may play a role in in the development of diabetes mellitus in cross-sectional studies and circulating NRG4 might be associated with imbalance in glucose metabolism and obesity.[meta-analysis] (PMID:31815951)
• Nrg-4 levels may be a good predictor of early detection of one or more diabetic microvascular complicationss (PMID:31999832)
• Negative Correlation between Neuregulin-4 and IL-9 Serum Levels in Patients with Coronary Artery Disease. (PMID:33463482)
• Is there a role for neuregulin 4 in human nonalcoholic fatty liver disease? (PMID:33989346)
• Serum neuregulin 4 (NRG-4) level and non-alcoholic fatty liver disease (NAFLD): A case-control study. (PMID:34159710)
• Mutations of NRG4 Contribute to the Pathogenesis of Nonalcoholic Fatty Liver Disease and Related Metabolic Disorders. (PMID:34261740)
• Neuregulin 4 (NRG4) - the hormone with clinical significance in gestational diabetes mellitus. (PMID:35603674)
• NGR4 and ERBB4 as Promising Diagnostic and Therapeutic Targets for Metabolic Disorders. (PMID:37369570)
• Neuregulin 4 (Nrg4) cooperates with melatonin to regulate the PRL expression via ErbB4/Erk signaling pathway as a potential prolactin (PRL) regulator. (PMID:38465779)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Nrg4	ENSMUSG00000032311
rattus_norvegicus	Nrg4	ENSRNOG00000015149

Paralogs (3): NRG1 (ENSG00000157168), NRG2 (ENSG00000158458), NRG3 (ENSG00000185737)

Protein

Protein identifiers

Pro-neuregulin-4, membrane-bound isoform — Q8WWG1 (reviewed: Q8WWG1)

All UniProt accessions (5): E9PJI7, H3BP63, Q0P6N6, Q7Z663, Q8WWG1

UniProt curated annotations — full annotation on UniProt →

Function. Low affinity ligand for the ERBB4 tyrosine kinase receptor. Concomitantly recruits ERBB1 and ERBB2 coreceptors, resulting in ligand-stimulated tyrosine phosphorylation and activation of the ERBB receptors. Does not bind to the ERBB1, ERBB2 and ERBB3 receptors.

Subunit / interactions. Interacts with ERBB4.

Subcellular location. Cell membrane Secreted.

Post-translational modifications. Proteolytic cleavage close to the plasma membrane on the external face leads to the release of the soluble growth factor form. Extensive glycosylation precedes the proteolytic cleavage.

Domain organisation. The cytoplasmic domain may be involved in the regulation of trafficking and proteolytic processing. Regulation of the proteolytic processing involves initial intracellular domain dimerization. ERBB receptor binding is elicited entirely by the EGF-like domain.

Similarity. Belongs to the neuregulin family.

RefSeq proteins (1): NP_612640* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000742	EGF	Domain

Pfam: PF00008

UniProt features (10 total): disulfide bond 3, chain 2, topological domain 2, transmembrane region 1, domain 1, glycosylation site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WWG1-F1	77.77	0.22

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (3): 9–23, 17–34, 36–45

Glycosylation sites (1): 39

Function

Pathways and Gene Ontology

Reactome pathways

17 pathways

ID	Pathway
R-HSA-1227986	Signaling by ERBB2
R-HSA-1236394	Signaling by ERBB4
R-HSA-1250196	SHC1 events in ERBB2 signaling
R-HSA-1250342	PI3K events in ERBB4 signaling
R-HSA-1250347	SHC1 events in ERBB4 signaling
R-HSA-1251985	Nuclear signaling by ERBB4
R-HSA-1257604	PIP3 activates AKT signaling
R-HSA-1963640	GRB2 events in ERBB2 signaling
R-HSA-1963642	PI3K events in ERBB2 signaling
R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-5673001	RAF/MAP kinase cascade
R-HSA-6785631	ERBB2 Regulates Cell Motility
R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-8847993	ERBB2 Activates PTK6 Signaling
R-HSA-8863795	Downregulation of ERBB2 signaling
R-HSA-9664565	Signaling by ERBB2 KD Mutants
R-HSA-9665686	Signaling by ERBB2 TMD/JMD mutants

MSigDB gene sets: 140 (showing top): LINDGREN_BLADDER_CANCER_CLUSTER_3_DN, GOMF_GROWTH_FACTOR_ACTIVITY, KEGG_ERBB_SIGNALING_PATHWAY, GOBP_ERBB_SIGNALING_PATHWAY, PID_ERBB4_PATHWAY, POU3F2_02, GOMF_SIGNALING_RECEPTOR_BINDING, GOBP_CELL_SURFACE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY, GEORGES_TARGETS_OF_MIR192_AND_MIR215, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_UP, GOMF_SIGNALING_RECEPTOR_REGULATOR_ACTIVITY, MIKKELSEN_MEF_ICP_WITH_H3K27ME3, PID_ERBB_NETWORK_PATHWAY, OHGUCHI_LIVER_HNF4A_TARGETS_UP, CHYLA_CBFA2T3_TARGETS_UP

GO Biological Process (2): ERBB4-ERBB4 signaling pathway (GO:0038138), signal transduction (GO:0007165)

GO Molecular Function (3): growth factor activity (GO:0008083), receptor ligand activity (GO:0048018), protein binding (GO:0005515)

GO Cellular Component (4): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-9 pathways:

Category	Pathways
Signaling by ERBB2	6
Signaling by ERBB4	3
Signaling by Receptor Tyrosine Kinases	2
Signaling by ERBB2 in Cancer	2
Intracellular signaling by second messengers	1
PI3K/AKT Signaling in Cancer	1
MAPK1/MAPK3 signaling	1
Negative regulation of the PI3K/AKT network	1
Signaling by PTK6	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
ERBB4 signaling pathway	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
receptor ligand activity	1
signaling receptor binding	1
signal transduction	1
signaling receptor activator activity	1
binding	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

626 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NRG4	ERBB4	Q15303	998
NRG4	NRG2	O14511	973
NRG4	ERBB3	P21860	968
NRG4	NRG3	P56975	945
NRG4	NRG1	P98202	892
NRG4	EGFR	P00533	886
NRG4	ERBB2	P04626	776
NRG4	AREG	P15514	725
NRG4	EGF	P01133	684
NRG4	PVALB	P20472	652
NRG4	BTC	P35070	644
NRG4	EPGN	Q6UW88	613
NRG4	EREG	O14944	586
NRG4	FGF21	Q9NSA1	582
NRG4	UCP1	P25874	553

IntAct

18 interactions, top by confidence:

A	B	Type	Score
FATE1	NRG4	psi-mi:“MI:0915”(physical association)	0.780
NRG4	FATE1	psi-mi:“MI:0915”(physical association)	0.780
NRG4	ERGIC3	psi-mi:“MI:0915”(physical association)	0.560
LHFPL5	NRG4	psi-mi:“MI:0915”(physical association)	0.560
CISD2	NRG4	psi-mi:“MI:0915”(physical association)	0.560
NRG4	CREB3	psi-mi:“MI:0915”(physical association)	0.370
NRG4	FATE1	psi-mi:“MI:0915”(physical association)	0.000
NRG4	ERGIC3	psi-mi:“MI:0915”(physical association)	0.000
NRG4	LHFPL5	psi-mi:“MI:0915”(physical association)	0.000
NRG4	CISD2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (8): NRG4 (Two-hybrid), NRG4 (Two-hybrid), FATE1 (Two-hybrid), NRG4 (Two-hybrid), NRG4 (Two-hybrid), NRG4 (Two-hybrid), LHFPL5 (Two-hybrid), NRG4 (Affinity Capture-RNA)

ESM2 similar proteins: D5K8A9, E7FEC4, O14944, O70534, O75129, O76095, O77049, O88823, O88824, O95727, P04441, P22934, P25118, P30931, P35070, P43303, P80370, Q02092, Q05928, Q09163, Q13145, Q149L7, Q3SXY7, Q5BVD1, Q60943, Q61521, Q6P9G4, Q7T2L7, Q80Z10, Q80ZD7, Q80ZD8, Q8BGE4, Q8C351, Q8C5C9, Q8HYZ0, Q8IYV9, Q8JZL1, Q8NFM7, Q8WWG1, Q90375

Diamond homologs: B1B5J0, P01132, P0DMY9, P0DMZ0, P15638, P86468, P86469, P98121, Q6QNF4, Q76CA1, Q8WWG1, Q94918, Q9R098, Q9WTX4, A2AJ76, A2ASS6, D3YXG0, G4SLH0, O01761, O08775, O14511, O35136, O35181, O35569, O60469, O89026, O93383, P07522, P12960, P13591, P14781, P22063, P28685, P35918, P43322, P56974, P56975, P57087, Q00968, Q02246

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
NRG4	up-regulates	ERBB4	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

21 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	18
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1608 predictions. Top by Δscore:

Variant	Effect	Δscore
15:75961824:TTA:T	donor_loss	1.0000
15:75961825:TAC:T	donor_loss	1.0000
15:75961826:A:AC	donor_gain	1.0000
15:75961826:AC:A	donor_gain	1.0000
15:75961826:ACCTG:A	donor_gain	1.0000
15:75961827:C:CT	donor_gain	1.0000
15:75961827:CC:C	donor_gain	1.0000
15:75961827:CCT:C	donor_gain	1.0000
15:75961827:CCTG:C	donor_gain	1.0000
15:75961827:CCTGC:C	donor_gain	1.0000
15:75961970:CGCAC:C	acceptor_gain	1.0000
15:75961972:CAC:C	acceptor_gain	1.0000
15:75969186:T:C	acceptor_gain	1.0000
15:76009307:A:C	acceptor_gain	1.0000
15:75955930:A:AC	donor_gain	0.9900
15:75955931:C:CC	donor_gain	0.9900
15:75955931:CT:C	donor_gain	0.9900
15:75961973:ACCT:A	acceptor_gain	0.9900
15:75969182:CAACT:C	acceptor_gain	0.9900
15:76005810:C:CC	acceptor_gain	0.9900
15:76009294:C:CC	acceptor_gain	0.9900
15:76009303:A:C	acceptor_gain	0.9900
15:76009306:CATA:C	acceptor_gain	0.9900
15:76009309:A:C	acceptor_gain	0.9900
15:76011216:ATTAC:A	donor_loss	0.9900
15:76011217:TTACC:T	donor_loss	0.9900
15:76011218:TAC:T	donor_loss	0.9900
15:76011220:CC:C	donor_loss	0.9900
15:76011284:TACCT:T	acceptor_loss	0.9900
15:76011286:CCTAA:C	acceptor_loss	0.9900

AlphaMissense

765 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:75961945:C:G	C45S	0.996
15:75961946:A:T	C45S	0.996
15:76009236:C:G	C23S	0.991
15:76009237:A:T	C23S	0.991
15:76009254:C:G	C17S	0.991
15:76009255:A:T	C17S	0.991
15:75961945:C:T	C45Y	0.989
15:75961946:A:G	C45R	0.989
15:76009203:C:G	C34S	0.989
15:76009204:A:T	C34S	0.989
15:76009256:A:C	F16L	0.989
15:76009256:A:T	F16L	0.989
15:76009258:A:G	F16L	0.989
15:75961945:C:A	C45F	0.988
15:75961972:C:G	C36S	0.988
15:75961973:A:T	C36S	0.988
15:75961954:C:A	G42V	0.987
15:76009237:A:G	C23R	0.986
15:76009255:A:G	C17R	0.986
15:76009257:A:C	F16C	0.985
15:76009203:C:T	C34Y	0.984
15:76009235:A:C	C23W	0.984
15:76009236:C:T	C23Y	0.983
15:75961944:A:C	C45W	0.982
15:75961948:C:G	R44P	0.982
15:75961973:A:G	C36R	0.982
15:76009204:A:G	C34R	0.982
15:75961954:C:T	G42E	0.981
15:76009202:A:C	C34W	0.980
15:76009254:C:T	C17Y	0.980

dbSNP variants (sampled 300 via entrez): RS1000007596 (15:75993197 G>A,T), RS1000053820 (15:76054500 C>T), RS1000077660 (15:76046822 C>T), RS1000102404 (15:75978042 C>G), RS1000105070 (15:75992848 T>G), RS1000105515 (15:75944039 C>G), RS1000114277 (15:76057099 T>G), RS1000166422 (15:75945391 C>G), RS1000204239 (15:75963461 C>G), RS1000211844 (15:76029303 A>G), RS1000234343 (15:75984787 A>G,T), RS1000248084 (15:75973480 C>T), RS1000277525 (15:75937137 CAT>C), RS1000303087 (15:76007481 G>C), RS1000340618 (15:76036834 G>T)

Disease associations

OMIM: gene MIM:610894 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

30 associations (top):

Study	Trait	p-value
GCST001765_18	Red blood cell traits	3.000000e-10
GCST001791_42	Urate levels	3.000000e-13
GCST002828_24	Urate levels in obese individuals	8.000000e-06
GCST004203_4	Diastolic blood pressure	3.000000e-09
GCST004601_129	Red blood cell count	5.000000e-20
GCST004601_130	Red blood cell count	2.000000e-14
GCST004604_10	Hematocrit	1.000000e-14
GCST004604_71	Hematocrit	2.000000e-26
GCST004615_102	Hemoglobin concentration	3.000000e-24
GCST006624_58	Systolic blood pressure	9.000000e-13
GCST007267_13	Systolic blood pressure	2.000000e-12
GCST007733_57	Serum uric acid levels	8.000000e-10
GCST007733_8	Serum uric acid levels	4.000000e-06
GCST007876_30	Estimated glomerular filtration rate	3.000000e-25
GCST008058_158	Estimated glomerular filtration rate	2.000000e-61
GCST008059_120	Estimated glomerular filtration rate	1.000000e-50
GCST008060_28	Estimated glomerular filtration rate	9.000000e-06
GCST008062_13	Blood urea nitrogen levels	5.000000e-30
GCST008745_13	Estimated glomerular filtration rate in non-diabetics	1.000000e-18
GCST008747_46	Estimated glomerular filtration rate	2.000000e-33
GCST008971_107	Urate levels	4.000000e-32
GCST008971_40	Urate levels	5.000000e-14
GCST008972_116	Urate levels	2.000000e-06
GCST008972_176	Urate levels	3.000000e-39
GCST009391_628	Metabolite levels	6.000000e-06
GCST90002383_231	Hematocrit	9.000000e-23
GCST90002383_232	Hematocrit	1.000000e-48
GCST90002384_344	Hemoglobin	2.000000e-20
GCST90002384_345	Hemoglobin	2.000000e-44
GCST90002403_495	Red blood cell count	6.000000e-41

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004509	hemoglobin measurement
EFO:0004531	urate measurement
EFO:0006336	diastolic blood pressure
EFO:0004305	erythrocyte count
EFO:0004348	hematocrit
EFO:0006335	systolic blood pressure
EFO:0004761	uric acid measurement
EFO:0010502	indoxyl sulfate measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

12 total (human), top 12 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
tris(2-butoxyethyl) phosphate	affects expression	1
sodium arsenite	decreases expression	1
2-palmitoylglycerol	increases expression	1
abrine	decreases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression	1
Silicon Dioxide	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Urethane	decreases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression	1
Cadmium Chloride	decreases expression	1
Okadaic Acid	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1Z8	Abcam HeLa NRG4 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.